Why IMU is a multi multi bagger, page-20845

So many thanks @Watmighthavben and to many others who give freely of their time to produce a timeline commentary on IMU in user friendly language.

The global bio tech sector is awash with bio techs who have developed interesting and compelling science, helmed by Directors and scientists with gold star top heavy CV’s. Very few of them ever manage to obtain commercial benefits before their cash burn rate swallows them or they try to fold into some other entity.

l will be brutally frank on the deal side. The informed market was aware a deal was under discussion in 2021, with whispers of $1ps , which saw the SP hit 61c. It had to relate to Her-Vaxx… what happened? In a moment of what in hindsight seems absolute hubris on the part of Chair Hopper, the deal was rejected. It was rumoured that Hopper thought the deal undervalued the product and would adversely affect the share price. I wonder whatever happened to ‘ a bird in the hand….’ thinking. This resulted in Axel Hoos being voted out by the personal holdings of his fellow Directors on the basis of a conflict of interest. I don’t believe he has ever spoken of what happened but it forms part of the IMU story.

Subsequently the platform has been flogged around the Asian market et al, and nothing has eventuated. Monil Shah is clearly not a rainmaker on the big stage or do his suggestions get overridden?

IMU has failed to get its story out to where it counts and showing up at the JP Morgan bio fest didn’t move the dial 12 months ago. IMU will have only itself to blame if it gets swallowed up for peanuts or gradually fades away in a red hot competitive oncology space.